Merck Grants License to LabCorp for Development of Test To Potentially Identify Patients Likely to Respond to …
WHITEHOUSE STATION, N.J.—-Merck today announced a non-exclusive license agreement with Laboratory Corporation of America® Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.
Nurses Join President Obama on Health Care Reform